BACKGROUND: The association between C-reactive protein (CRP) and cardiovascular (CV) mortality by gender has not been previously described using a data set that is representative of the US population. METHODS: We used Cox proportional hazards models to explore gender differences in CRP-associated mortality via the National Health and Nutrition Examination Survey III 1988-1994 linked to the National Death Index with mortality follow-up through 2006. We examined CV mortality as well as all-cause mortality hazards. RESULTS: The final sample size included a total of 13,878 individuals (7,364 women and 6,514 men) with a median follow up of 18.2 years. All models controlled for race, age, smoking, high-density lipoprotein, hypertension, diabetes mellitus, waist circumference, and total cholesterol. Men with a CRP >3.0 mg/L relative to those with a CRP ≤3.0 mg/L had elevated CV mortality hazards (hazard ratio [HR] 1.79, 95% CI 1.23-2.60) and all-cause mortality hazards (HR 1.57, 95% CI 1.29-1.90). In women, elevated CRP was not significantly associated with either increased CV (HR 1.20, 95% CI 0.90-1.59) or all-cause mortality hazards (HR 1.09, CI 0.93-1.29). CONCLUSION: National guidelines from various agencies that make recommendations on the diagnostic and prognostic use of CRP have treated men and women equally. We find that there may be reason to tailor recommendations based upon one's gender.
BACKGROUND: The association between C-reactive protein (CRP) and cardiovascular (CV) mortality by gender has not been previously described using a data set that is representative of the US population. METHODS: We used Cox proportional hazards models to explore gender differences in CRP-associated mortality via the National Health and Nutrition Examination Survey III 1988-1994 linked to the National Death Index with mortality follow-up through 2006. We examined CV mortality as well as all-cause mortality hazards. RESULTS: The final sample size included a total of 13,878 individuals (7,364 women and 6,514 men) with a median follow up of 18.2 years. All models controlled for race, age, smoking, high-density lipoprotein, hypertension, diabetes mellitus, waist circumference, and total cholesterol. Men with a CRP >3.0 mg/L relative to those with a CRP ≤3.0 mg/L had elevated CV mortality hazards (hazard ratio [HR] 1.79, 95% CI 1.23-2.60) and all-cause mortality hazards (HR 1.57, 95% CI 1.29-1.90). In women, elevated CRP was not significantly associated with either increased CV (HR 1.20, 95% CI 0.90-1.59) or all-cause mortality hazards (HR 1.09, CI 0.93-1.29). CONCLUSION: National guidelines from various agencies that make recommendations on the diagnostic and prognostic use of CRP have treated men and women equally. We find that there may be reason to tailor recommendations based upon one's gender.
Authors: Jordan Gaines; Alexandros N Vgontzas; Julio Fernandez-Mendoza; Ilia Kritikou; Maria Basta; Edward O Bixler Journal: Brain Behav Immun Date: 2014-12-20 Impact factor: 7.217
Authors: Shoham Choshen-Hillel; Ahmad Ishqer; Fadi Mahameed; Joel Reiter; David Gozal; Alex Gileles-Hillel; Itai Berger Journal: Med Educ Date: 2020-08-28 Impact factor: 6.251
Authors: Mark G O'Doherty; Torben Jørgensen; Anders Borglykke; Hermann Brenner; Ben Schöttker; Tom Wilsgaard; Galatios Siganos; Maryam Kavousi; Maria Hughes; Aysel Müezzinler; Bernd Holleczek; Oscar H Franco; Albert Hofman; Paolo Boffetta; Antonia Trichopoulou; Frank Kee Journal: Eur J Epidemiol Date: 2014-11-25 Impact factor: 8.082
Authors: Marjan Motie; Lorraine S Evangelista; Tamara Horwich; Dawn Lombardo; Frank Zaldivar; Michele Hamilton; Gregg C Fonarow Journal: Exp Ther Med Date: 2014-04-08 Impact factor: 2.447